Press release
Pfizer Seeking Consolidation of Zoloft Birth Defects Lawsuits
Nadrich & Cohen, LLP reports that Pfizer is seeking to consolidate a number of federal Zoloft birth defects lawsuits into a multidistrict litigation.Los Angeles, CA, February 1, 2012 – Pfizer has reportedly asked a federal judicial panel to centralize a number of Zoloft birth defects lawsuits filed against the company. If the motion is granted, the cases would be consolidated for pretrial proceedings and heard in a federal district court. Oral arguments are scheduled for May 31.
According to court documents, the motion was filed on January 18. Pfizer is reportedly seeking to have an estimated 59 lawsuits consolidated before a judge in the U.S. District Court for the Southern District of New York. The company’s headquarters are located in New York City.
The majority of the cases are currently pending in the U.S. District Court for the Eastern District of Pennsylvania. In their motion, Pfizer suggested the Northern and Southern Districts of Mississippi and the Northern District of Ohio as alternate locations.
The plaintiffs have alleged that Zoloft, an SSRI antidepressant, caused serious birth defects, including newborn persistent pulmonary hypertension (PPHN), various heart defects, lung and abdominal defects and other complications. Zoloft (sertraline) was first approved by the FDA in 1991 to treat numerous conditions, including depression, obsessive-compulsive disorder and anxiety.
Research studies have suggested that the use of an SSRI antidepressant may elevate the risk of giving birth to a child with serious defects. Despite these reports, the Food and Drug Administration continues to support the use of these drugs to treat women with depression.
Women who gave birth to children with serious defects after taking Zoloft or another SSRI antidepressant are encouraged to complete a MedWatch form by visiting the FDA’s website. Patients are also urged to seek the aid of an experienced personal injury lawyer to discuss their legal rights.
Nadrich & Cohen LLP is offering confidential, no-cost consultations to individuals across the country who believe their child was harmed by Zoloft. Help is available by calling the firm’s injury hotline at 1-800-718-4658.
Nadrich & Cohen LLP is a national law firm with offices in Los Angeles, Sacramento, San Diego and other cities throughout California specializing in handling mass tort actions and representing individuals in cases involving pharmaceutical companies and medical device manufacturers. The firm is committed to achieving the best outcome possible in every case and has recovered over $200 million in settlements on behalf of its clients.
In addition to handling Zoloft birth defects claims, the firm is also investigating cases involving Accutane, Actos, Avandia, Fosamax, Paxil, Vaginal Mesh, Wright Conserve Hips, Yaz, Yasmin, Stevens-Johnson Syndrome, Benzene, Reflex Sympathy Dystrophy, Fen Phen and PPH, Depakote and Reglan. For more information, visit www.personalinjurylawcal.com.
Jennifer Poole
National Client Intake Coordinator
Nadrich & Cohen LLP
12100 Wilshire Blvd.
Suite 1250
Los Angeles, CA 90025
800-718-4658
info@personalinjurylawcal.com
www.personalinjurylawcal.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pfizer Seeking Consolidation of Zoloft Birth Defects Lawsuits here
News-ID: 209518 • Views: …
More Releases from Nadrich & Cohen LLP
Yaz Lawsuit Settlements Reach $142 Million
Nadrich & Cohen, LLP reports that Bayer is continuing to offer settlements to plaintiffs involved in federal Yaz side effects litigation.
Los Angeles, CA, April 27, 2012 – Nadrich & Cohen, LLP reports that German drug-maker Bayer AG has settled approximately 651 Yaz side effects lawsuits totaling $142 million. Earlier this month, it was reported that the drug-maker had reached settlements in approximately 500 cases filed by women who claimed…
Yaz, Yasmin to Get New Labels as FDA Warns of Blood Clot Risk
Nadrich & Cohen, LLP reports that Yaz and similar birth control pills are to receive updated warning labels advising patients of the risk for developing serious blood clots.
Los Angeles, CA, April 10, 2012 – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has ordered Bayer to produce new warning labels for several of its oral contraceptives, including Yaz, Yasmin and Beyaz.…
FDA Schedules Advisory Panel Meeting to Discuss Metal Hip Safety
Nadrich & Cohen, LLP reports that the FDA has scheduled an advisory panel to discuss the safety of metal hip implants.
Los Angeles, CA, March 29, 2012 – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has a scheduled an advisory panel meeting to discuss the safety of metal hip implants and all-metal hip resurfacing systems.
The two-day panel, which is expected…
Pradaxa Side Effects Lawsuits Filed in Federal Court
Nadrich & Cohen, LLP reports that three Pradaxa side effects lawsuits have been filed in federal courts across the country.
Los Angeles, CA, March 7, 2012 – National law firm Nadrich & Cohen, LLP has learned that three Pradaxa side effects lawsuits have been filed against Boehringer Ingelheim, the drug’s manufacturer. The cases were filed in federal district courts located in Tennessee, Kentucky and Louisiana and it’s believed they are the…
More Releases for Zoloft
Depression Drugs Market Uncover Challenges and Opportunities with Intellipharmac …
Selective serotonin reuptake inhibitors (SSRIs) were launched in the mid to late 1980s. This generation of antidepressants is now the most common class used for depression. Examples include citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil, Pexeva), fluoxetine (Prozac, Sarafem), and sertraline (Zoloft).
SSRIs include fluoxetine (Prozac), paroxetine (Paxil, Pexeva), sertraline (Zoloft), citalopram (Celexa) and escitalopram (Lexapro). Serotonin and norepinephrine reuptake inhibitors (SNRIs).
The Global Depression Drugs Market report clutch an inspection of main…
2018 Zoloft Market | Size, Trends, Industry Analysis, Leading Players & Future F …
“Sertraline, sold under the trade name ‘Zoloft’ among others, is an antidepressant of the selective serotonin reuptake inhibitor class. It is primarily used for major depressive disorder, obsessive–compulsive disorder, panic disorder, and social anxiety disorder. Effectiveness is similar to other antidepressants.”
Zoloft Market report offers a valuable tool to assess the latest market statistics and market scenario. The report presents the strategies and research methodology followed to clarify the industry aspects.…
Post Traumatic Stress Disorder (PTSD) Therapeutics Market to Remain Lucrative Du …
Post-traumatic stress disorder (PTSD) is a psychological condition that occurs in individuals of any age and gender. Its symptoms can show up immediately after a traumatic experience or with the course of time. It is one of the most common psychological disorders, affecting about 8 mn adult Americans and an annual incidence rate of close to 3.5% across the globe. Its first line of treatments includes counseling and psychotherapy. The…
Post-Traumatic Stress Disorder Therapeutics Market Projected to Discern Stable E …
Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market: Overview
Post-traumatic stress disorder (PTSD) is a psychological condition that occurs in individuals of any age and gender. Its symptoms can show up immediately after a traumatic experience or with the course of time. It is one of the most common psychological disorders, affecting about 8 mn adult Americans and an annual incidence rate of close to 3.5% across the globe. Its first line…
Global Depression Drugs Market 2017 - Viibryd, Celexa, Lexapro, Fetzima, Zoloft, …
Global Depression Drugs Market 2017 Survival Strategies explore Economic Impact in Global Industries Manufactures, Growth, Size, Share, Trends, Development Challenges and Opportunities till 2022
A Research study on " Global Depression Drugs Market 2017-2022 " represent the market share and size of Depression Drugs in international Industry. MRS Research Group added latest market research report by QY Research. Research Report provides an essential information and statistically evaluated data about the Depression…
Worldwide Analysis on Post-Traumatic Stress Disorder (PTSD) Therapeutics Market …
Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market: Overview
Post-traumatic stress disorder (PTSD) is a psychological condition that occurs in individuals of any age and gender. Its symptoms can show up immediately after a traumatic experience or with the course of time. It is one of the most common psychological disorders, affecting about 8 mn adult Americans and an annual incidence rate of close to 3.5% across the globe. Its first line…